193 related articles for article (PubMed ID: 27993997)
21. Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
Bacsur P; Iliás Á; Resál T; Kata D; Molnár T; Farkas K
Aliment Pharmacol Ther; 2023 Jul; 58(2):262-263. PubMed ID: 37352154
[No Abstract] [Full Text] [Related]
22. [Problems of gastrointestinal therapy in pregnancy].
Piccione E
Clin Ter; 1987 Jul; 122(1):55-9. PubMed ID: 2973897
[No Abstract] [Full Text] [Related]
23. Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy.
Crouwel F; Waaijenberg-Warmenhoven P; Buiter HJC; de Boer NK
J Crohns Colitis; 2021 Jul; 15(7):1244-1245. PubMed ID: 33350449
[No Abstract] [Full Text] [Related]
24. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.
Lissner D; Glauben R; Allers K; Sonnenberg E; Loddenkemper C; Schneider T; Siegmund B
Am J Gastroenterol; 2018 Jan; 113(1):146-148. PubMed ID: 29311733
[No Abstract] [Full Text] [Related]
26. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
27. Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis.
Westerveld D; Grajo J; Beattie L; Glover S
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28501828
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
29. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
Richard N; Vuitton L; Fumery M
Aliment Pharmacol Ther; 2023 Mar; 57(6):741-742. PubMed ID: 36821749
[No Abstract] [Full Text] [Related]
30. Combination of vedolizumab and immunomodulators in ulcerative colitis.
Pinton P
J Gastroenterol Hepatol; 2021 Dec; 36(12):3556. PubMed ID: 34519096
[No Abstract] [Full Text] [Related]
31. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
Osterman MT; Rosario M; Lasch K; Barocas M; Wilbur JD; Dirks NL; Gastonguay MR
Aliment Pharmacol Ther; 2019 Feb; 49(4):408-418. PubMed ID: 30663076
[TBL] [Abstract][Full Text] [Related]
32. Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis?
Yamamoto T
Aliment Pharmacol Ther; 2023 Sep; 58(5):546-547. PubMed ID: 37559519
[No Abstract] [Full Text] [Related]
33. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
34. Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis.
Faria LM; Oliveira MM; Faria AA; Vasconcellos AVO; Cançado GGL
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):513-514. PubMed ID: 36827537
[No Abstract] [Full Text] [Related]
35. Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient.
Wenzel AA; Strople J; Melin-Aldana H; Brown JB
J Pediatr Gastroenterol Nutr; 2020 Jul; 71(1):e47-e48. PubMed ID: 32304548
[No Abstract] [Full Text] [Related]
36. A Case of Vedolizumab-induced Acute Allergic Reaction in a Patient With Refractory Ulcerative Colitis.
Xie Y; Li H; Zhou L; Tian F
Inflamm Bowel Dis; 2022 Jul; 28(7):e103. PubMed ID: 35134937
[No Abstract] [Full Text] [Related]
37. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
Jin Y; Lin Y; Lin LJ; Zheng CQ
World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
[TBL] [Abstract][Full Text] [Related]
38. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
[No Abstract] [Full Text] [Related]
40. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
